The FDA approved Pfizer's Inlyta, saying the drug works in patients with metastatic kidney cancer whose initial therapy did not work. Inlyta, or axitinib, delayed tumor progression by two months during a head-to-head trial
with Nexavar, a targeted agent by Bayer and Onyx Pharmaceuticals.

Full Story:

Related Summaries